Strategic партнерство PolyPid is actively pursuing commercial partnerships for D-PLEX100 in the US and Canada through an exclusive agreement with Azurity Pharmaceuticals, indicating a direct sales channel expansion opportunity and potential co-marketing arrangements to accelerate market access.

Surgical focus The core value proposition centers on localized, long-acting drug delivery at surgical sites to prevent infections and improve outcomes, suggesting strong sales opportunities with hospitals, surgical centers, and health systems prioritizing SSI reduction and antibiotic stewardship.

Phase 3 momentum Ongoing and upcoming Phase 3 SHIELD II data presentations position D-PLEX100 for late-stage adoption; engage clinical liaisons and procurement teams early to align with future commercialization timelines and reimbursement discussions.

Financial readiness With substantial funding and a mid-market revenue range, PolyPid has the capital and scale to support large pilot programs, contracts, and regional deployments, making it feasible to pursue multi-site hospital agreements and strategic pilots.

Tech and operations fit A diversified tech stack and cloud-based infrastructure support streamlined digital outreach, CRM, and supply chain coordination, enabling scalable sales operations, accurate forecasting, and efficient field execution for new product launches.